Federal Register / Vol. 85, No. 231 / Tuesday, December 1, 2020 / Notices 77243 

SRL, Bassano del Grappa VI, ITALY; 

Inergy Systems LLC, Tempe, AZ; 

Intermatic Incorporated, Spring Grove, 

IL; Jasco Products, Oklahoma City, OK; 

JLabs Corporation, Tokyo, JAPAN; 

Johnson Controls Inc., Milwaukee, WI; 

Leak Intelligence LLC, Franklin, TN; 

Leviton Manufacturing Company, Inc., 

Melville, NY; Logic Group A/S, 

Broendby, DENMARK; MERCURY 

Corporation, Incheon, SOUTH KOREA; 

Mitsumi Electric Co., LTD, Tokyo, 

JAPAN; MIWA LOCK CO., LTD, Tokyo, 

JAPAN; MK Logic GmbH, Zwickau, 

GERMANY; Nanjing IoTx Intelligent 

Technology Co., Ltd., Nanjing, 

PEOPLE’S REPUBLIC OF CHINA; 

NAPCO SECURITY TECHNOLOGIES, 

Amityville, NY; Ness Corporation Pty 

Limited, New South Wales, 

AUSTRALIA; Nexa Trading AB, Askim, 

SWEDEN; NIE–TECH CO., LTD., 

Dongguan City, PEOPLE’S REPUBLIC 

OF CHINA; Ningbo Doooya Mechanic & 

Electronic Technology Co., Ltd., Ningbo, 

PEOPLE’S REPUBLIC OF CHINA; 

Nortek Security & Control, Carlsbad, 

CA; OBLO Living, Novi Sad, SERBIA; 

PassivSystems Limited, Berkshire, 

UNITED KINGDOM; Perenio IOT spol 

s.r.o., Ricany-Jazlovice, CZECH 

REPUBLIC; Philio Technology 

Corporation, New Taipei City, 

TAIWAN; Quby B.V., Amsterdam, THE 

NETHERLANDS; Rehau AG + Co, 

Rehau, GERMANY; Remote 

Technologies Inc., Shakopee, MN; 

Remotec Technology Limited, Kowloon, 

HONG KONG ; Rently Keyless, Los 

Angeles, CA; Resideo Technologies, 

Inc., Mellville, NY; RISCO Group Ltd., 

Rishon, ISRAEL; Sagemcom Broadband 

SAS, Rueil-Malmaison Cedex, FRANCE; 

SALTO Systems, Oiartzun, SPAIN; 

Schlage Lock Company, LLC, Carmel, 

IN; Secure Meters UK Ltd., Bristol, 

UNITED KINGDOM; Sensative AB, 

Lund, SWEDEN; Sharp Corporation, 

Osaka-fu, JAPAN; Sheenway Asia 

Limited, Kowloon, HONG KONG; 

Shenzhen Kaadas Intelligent 

Technology Co., Ltd, Shenzhen, 

PEOPLE’S REPUBLIC OF CHINA; 

SHENZHEN NEO ELECTRONICS CO., 

LTD, Shenzhen, PEOPLE’S REPUBLIC 

OF CHINA; SHENZHEN SHYUGJ 

TECHNOLOGY CO., LTD, Shenzhen, 

PEOPLE’S REPUBLIC OF CHINA; 

Shenzhen Sunricher Technology 

Limited, Shenzhen, PEOPLE’S 

REPUBLIC OF CHINA; Smart Systems 

LLC, Moscow, RUSSIA; SmartRent.com, 

INC, Scottsdale, AZ; Spectrum Brands 

Inc., Lake Forest, CA; Swidget Corp, 

Kingston, CANADA; Taiwan Fu Hsing 

Industrial Co., Ltd, Kaohsiung City, 

TAIWAN; TechniSat Digital GmbH, 

Daun, GERMANY; TEM AG, Chur, 

SWEDEN; Teptron AB, Varburg, 

SWEDEN; Thinka BV, Amsterdam, THE 

NETHERLANDS; TLJ Access Control, 

East Yorkshire, UNITED KINGDOM; 

Transducers Direct, Cincinnati, OH; Tri 

plus grupa d.o.o. (Zipato), Zagreb, 

CROATIA; Ubitech Limited, Tsuen 

Wan, HONG KONG; Universal 

Electronics Inc., Scottsdale, AZ; 

Universal Remote Control, Inc., 

Harrison, NY; VDA Group SpA a S.U., 

Pordenone, ITALY; Viewqwest Pte Ltd., 

Singapore, SINGAPORE; Vision-Elec. 

Technology Co., Ltd., Tainan City, 

TAIWAN; Webee Corporation, 

Sunnyvale, CA; WeBeHome, Bromma, 

SWEDEN; WiDom Srl, Cagliari, ITALY; 

Yardi Systems, Goleta, CA; Danalock 

ApS, Harlev, DENMARK; Pepper One 

GmbH, Zwickau, GERMANY; and ADT, 

Boca Raton, FL. 

Z-Wave Alliance Inc. was formed as a 

Delaware non-stock member 

corporation. The general area of Z-Wave 

Alliance Inc.’s planned activity is to 

support the development and extension 

of the Z-Wave wireless communication 

protocol and promote the protocol as a 

key enabling technology for ‘smart’ 

home and business applications, and to 

undertake such other activities as may 

from time to time be appropriate to 

further the purposes and achieve the 

goals set forth above. 

Membership in Z-Wave Alliance, Inc. 

remains open and Z-Wave Alliance, Inc. 

intends to file additional written 

notifications disclosing all changes in 

membership. 

Suzanne Morris, 

Chief, Premerger and Division Statistics Unit, 

Antitrust Division. 

[FR Doc. 2020–26453 Filed 11–30–20; 8:45 am] 

BILLING CODE 4410–11–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–508F] 

Final Adjusted Aggregate Production 

Quotas for Schedule I and II Controlled 

Substances and Assessment of 

Annual Needs for the List I Chemicals 

Ephedrine, Pseudoephedrine, and 

Phenylpropanolamine for 2020 

AGENCY: Drug Enforcement 

Administration, Department of Justice. 

ACTION: Final order. 

SUMMARY: This final order establishes 

the final adjusted 2020 aggregate 

production quotas for controlled 

substances in schedules I and II of the 

Controlled Substances Act and the 

assessment of annual needs for the list 

I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine. 

DATES: This order is effective December 

1, 2020. 

FOR FURTHER INFORMATION CONTACT: 

Scott A. Brinks, Regulatory Drafting and 

Policy Support Section, Diversion 

Control Division, Drug Enforcement 

Administration; Mailing Address: 8701 

Morrissette Drive, Springfield, VA 

22152, Telephone: (571) 362–3261. 

SUPPLEMENTARY INFORMATION: 

Legal Authority 

Section 306 of the Controlled 

Substances Act (CSA) (21 U.S.C. 826) 

requires the Attorney General to 

establish aggregate production quotas 

(APQ) for each basic class of controlled 

substances listed in schedules I and II 

and for the list I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine. The Attorney 

General has delegated this function to 

the Administrator of the Drug 

Enforcement Administration (DEA) 

pursuant to 28 CFR 0.100. 

Background 

DEA published the 2020 established 

APQ for controlled substances in 

schedules I and II and for the 

assessment of annual needs (AAN) for 

the list I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine in the Federal 

Register on December 2, 2019. 84 FR 

66014. DEA is committed to preventing 

and limiting diversion by enforcing laws 

and regulations regarding controlled 

substances and the list I chemicals 

ephedrine, pseudoephedrine, and 

phenylpropanolamine, while meeting 

the legitimate medical, scientific, and 

export needs of the United States. This 

notice stated that the Administrator 

would adjust, as needed, the established 

APQ in 2020 in accordance with 21 CFR 

1303.13 and 21 CFR 1315.13. 

In response to the public health 

emergency declared by the Secretary of 

Health and Human Services (HHS) on 

January 31, 2020, DEA published the 

final order titled ‘‘Adjustments to 

Aggregate Production Quotas for Certain 

Schedule II Controlled Substances and 

Assessment of Annual Needs for the List 

I Chemicals Ephedrine and 

Pseudoephedrine for 2020’’ on April 10, 

2020. (85 FR 20302). While the 

adjustments were effective immediately, 

all interested persons were invited to 

comment on or object to the adjustments 

on or before May 11, 2020. 

The 2020 proposed adjusted APQ for 

controlled substances in schedules I and 

II and AAN for the list I chemicals 


khammond on DSKJM1Z7X2PROD with NOTICES4
77244 Federal Register / Vol. 85, No. 231 / Tuesday, December 1, 2020 / Notices 

ephedrine, pseudoephedrine, and 

phenylpropanolamine were 

subsequently published in the Federal 

Register on September 1, 2020, (85 FR 

54414), after consideration of the 

criteria outlined in that notice. All 

interested persons were invited to 

comment on or object to the proposed 

APQs and AANs on or before October 1, 

2020. 

Comments Received 

DEA received five timely comments 

and one untimely comment in response 

to the April Federal Register notice and 

nine comments in response to the 

September Federal Register notice from 

patients, DEA-registered entities, and 

non-DEA entities. The comments 

included appreciation of DEA’s 

response to the public health 

emergency, concerns about potential 

drug shortages, interference with doctorpatient relationships, and comments 

outside the scope of this final order. 

Issue: Commenters expressed 

appreciation of DEA’s flexibility in 

responding to the nationwide public 

health emergency declared by the 

Secretary of HHS on January 31, 2020, 

by adjusting APQ for select schedule II 

controlled substances and list I 

chemicals. 

DEA Response: DEA acknowledges 

the expressions of appreciation to 

changes in the APQ and AAN. The 

adjustments to select schedule II 

controlled substances and list I 

chemicals occurred after DEA consulted 

with HHS and determined the 

utilization rates for these drugs 

substantially increased due to the 

treatment regimens for ventilator 

patients stricken with the Coronavirus 

Disease of 2019 (COVID–19) compared 

to the previously estimated annual 

consumption rates. While the estimates 

from HHS provided a wide range in the 

number of patients that would require 

ventilation treatment due to COVID–19, 

DEA could, under 21 CFR 1303.13 and 

1315.13, adjust the APQ and AAN for 

schedule II controlled substances and 

list I chemicals, respectively, to ensure 

manufacturing activities cover the upper 

range of the estimate could occur in a 

timely manner. DEA highlights factor 21 

CFR 1303.13(b)(5) specifically, which 

allowed the Acting Administrator to 

increase the APQ and AAN for select 

controlled substances and list I 

chemicals to meet additional estimated 

medical needs as determined by HHS 

due to the unforeseen emergency caused 

by the COVID–19 pandemic. 

Issue: Commenters expressed general 

concerns that decreasing the APQ of 

controlled substances could lead to 

shortages of controlled substance 

medications. 

One DEA-registered entity submitted 

a comment requesting the APQ for 

hydrocodone (for sale) and oxycodone 

(for sale) be sufficient to provide for the 

estimated medical, scientific, research, 

and industrial needs of the United 

States, for export requirements, and for 

the establishment and maintenance of 

reserve stocks. 

DEA Response: DEA sets APQ in a 

manner to ensure that the estimated 

medical, scientific, research, industrial 

needs of the United States, lawful 

export requirements, and for the 

establishment and maintenance of 

reserve stocks. As discussed in both 

notices for adjustments, any 

adjustments to the APQ for controlled 

substances is based on factors set forth 

in 21 CFR 1303.13. In the event of a 

shortage, the CSA provides a 

mechanism under which DEA will, in 

appropriate circumstances, increase 

quotas to address shortages. 21 U.S.C. 

826(h). Under 21 U.S.C. 826(h)(1), after 

receiving a request to address a 

shortage, DEA has 30 days to complete 

review of the request and determine 

whether adjustments are necessary to 

address the shortage. If adjustments are 

necessary, DEA is required to increase 

the APQ and individual production 

quotas to alleviate the shortage. Id. If 

DEA determines adjustments are not 

necessary, DEA is required to ‘‘provide 

a written response detailing the basis for 

the . . . determination.’’ Id. In addition 

to what Section 826(h)(1) requires, 

when DEA is notified of an alleged 

shortage, DEA will confer with the U.S. 

Food and Drug Administration and 

relevant manufacturers regarding the 

amount of material in physical 

inventory, current quota granted, and 

the estimated legitimate medical need, 

to determine whether a quota 

adjustment is necessary to alleviate any 

factually valid shortage. 

In accordance with 21 CFR 1303.13, 

DEA considered the comments for 

hydrocodone (for sale) and oxycodone 

(for sale), and the Acting Administrator 

determined the proposed adjusted 2020 

APQs for these substances as published 

in the Federal Register on September 1, 

2020, (85 FR 54414), are sufficient to 

meet the current 2020 estimated 

medical, scientific, research, and 

industrial needs of the United States, 

and to provide for adequate reserve 

stock. 

Issue: DEA received comments of 

general concerns alleging decreases to 

the APQ interfered with doctor-patient 

relationships. 

DEA Response: In determining the 

APQ, DEA considers prescriptions that 

have been issued. However, DEA does 

not interfere with doctor-patient 

relationships. Doctors authorized to 

dispense controlled substances are 

responsible for adhering to the laws and 

regulations set forth under the CSA, 

which requires doctors to only write 

prescriptions for a legitimate medical 

need. DEA is responsible for enforcing 

controlled substance laws and 

regulations, and is committed to 

ensuring an adequate and uninterrupted 

supply of controlled substances in order 

to meet the demand of legitimate 

medical, scientific, and export needs of 

the United States. 

Untimely Comment Issue: The DEA 

received one comment from a DEAregistered entity for previously 

established value of the 2020 AAN for 

pseudoephedrine (for conversion), 

requesting an increase because the 

established AAN is not adequate to 

cover the commenter’s new projected 

need for 2020. 

DEA Response: The comment was 

received in between the comment 

periods for the two notices of 

adjustment. Even though the comment 

was outside the comment period that 

ended on May 11, 2020, DEA 

considered this comment as part of the 

second comment period ending on 

October 1, 2020, when setting the final 

2020 AAN. 

Out of Scope Comments: DEA 

received comments on issues outside 

the scope of this final order. The 

comments were general in nature and 

raised issues of specific medical 

illnesses, medical treatments, and 

medication costs, and therefore, are 

outside of the scope of this Final Order 

for 2020 and do not impact the original 

analysis involved in finalizing the 2020 

APQ. 

Analysis for Final Adjusted 2020 

Aggregate Production Quotas and 

Assessment of Annual Needs 

In determining the final adjusted 2020 

APQ and AAN, DEA has considered the 

above comments relevant to this Final 

Order for calendar year 2020, along with 

the factors set forth in 21 CFR 1303.13 

and 21 CFR 1315.13, in accordance with 

21 U.S.C. 826(a). DEA has also 

considered other relevant factors, 

including the 2019 year-end inventories, 

initial 2020 manufacturing and import 

quotas, 2020 export requirements, actual 

and projected 2020 sales, research and 

product development requirements, 

additional applications received, and 

the extent of any diversion of the 

controlled substance in the class. Based 

on all of the above, the Acting 

Administrator is adjusting the 2020 

APQ for the following: Increases for 


khammond on DSKJM1Z7X2PROD with NOTICES4
Federal Register / Vol. 85, No. 231 / Tuesday, December 1, 2020 / Notices 77245 

Amphetamine (for sale) and 

Methamphetamine, based on the data 

received since the publication of the 

2020 proposed adjustment for APQ and 

AAN in the Federal Register on 

September 1, 2020 (85 FR 54414); 

increases for Crotonyl Fentanyl, 

Ethylone, and Isotonitazene due to the 

publication of their schedule I 

temporary controlled status; and 

increases for Etonitazene due to 

additional manufacturers entering the 

reference standard market. This final 

order reflects those adjustments. 

Pursuant to the above, the Acting 

Administrator hereby finalizes the 2020 

APQ for the following schedule I and II 

controlled substances and the 2020 

AAN for the list I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine, expressed in 

grams of anhydrous acid or base, as 

follows: 

Basic class 

Final revised 

2020 quotas 

(g) 

Temporarily Scheduled Substances 

Crotonyl fentanyl .................................................................................................................................................................................. 25 

Ethylone ............................................................................................................................................................................................... 25 

Isotonitazene ........................................................................................................................................................................................ 25 

Schedule I 

1-[1-(2-Thienyl)cyclohexyl]pyrrolidine .................................................................................................................................................. 20 

1-(1-Phenylcyclohexyl)pyrrolidine ........................................................................................................................................................ 15 

1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine .................................................................................................................................. 10 

1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) ............................................................................................................................ 30 

1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) ........................................................................................................................... 30 

1-Benzylpiperazine .............................................................................................................................................................................. 25 

1-Methyl-4-phenyl-4-propionoxypiperidine ........................................................................................................................................... 10 

1-[1-(2-Thienyl)cyclohexyl]piperidine ................................................................................................................................................... 15 

2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E) ........................................................................................................................... 30 

2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D) ........................................................................................................................ 30 

2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N) .......................................................................................................................... 30 

2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P) ................................................................................................................... 30 

2-(2,5-Dimethoxyphenyl)ethanamine (2C-H) ....................................................................................................................................... 100 

2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36) ........................ 30 

2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C) ........................................................................................................................ 30 

2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82) ........................ 25

2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I) .............................................................................................................................. 30 

2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5) .................................. 30 

2,5-Dimethoxy-4-ethylamphetamine (DOET) ...................................................................................................................................... 25 

2,5-Dimethoxy-4-(n)-propylthiophenethylamine ................................................................................................................................... 25 

2,5-Dimethoxyamphetamine (DMA) .................................................................................................................................................... 25 

2-(4-Ethylthio-2,5-dimethoxyphenyl)ethanamine (2C-T-2) .................................................................................................................. 30 

2-(4-(Isopropylthio)-2,5-dimethoxyphenyl)ethanamine (2C-T-4) ......................................................................................................... 30 

3,4,5-Trimethoxyamphetamine ............................................................................................................................................................ 30 

3,4-Methylenedioxyamphetamine (MDA) ............................................................................................................................................ 55 

3,4-Methylenedioxymethamphetamine (MDMA) ................................................................................................................................. 50 

3,4-Methylenedioxy-N-ethylamphetamine (MDEA) ............................................................................................................................. 40 

3,4-Methylenedioxy-N-methylcathinone (methylone) .......................................................................................................................... 40 

3,4-Methylenedioxypyrovalerone (MDPV) ........................................................................................................................................... 35 

3-Fluoro-N-methylcathinone (3-FMC) .................................................................................................................................................. 25 

3-Methylfentanyl ................................................................................................................................................................................... 30 

3-Methylthiofentanyl ............................................................................................................................................................................. 30 

4-Bromo-2,5-dimethoxyamphetamine (DOB) ...................................................................................................................................... 30 

4-Bromo-2,5-dimethoxyphenethylamine (2-CB) .................................................................................................................................. 25 

4-Chloro-alpha-pyrrolidinovalerophenone (4-chloro-alpha-PVP) ......................................................................................................... 25 

1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1 H-indazole-3-carboximide (4CN-Cumyl-Butinaca) ........................................................ 25 

4-Fluoroisobutyryl fentanyl ................................................................................................................................................................... 30 

4-Fluoro-N-methylcathinone (4-FMC; Flephedrone) ........................................................................................................................... 25 

4-Methyl-N-ethylcathinone (4-MEC) .................................................................................................................................................... 25 

4-Methoxyamphetamine ...................................................................................................................................................................... 150 

4-Methyl-2,5-dimethoxyamphetamine (DOM) ...................................................................................................................................... 25 

4-Methylaminorex ................................................................................................................................................................................ 25 

4-Methyl-N-methylcathinone (mephedrone) ........................................................................................................................................ 45 

4-Methyl-alpha-ethylaminopentiophenone (4-MEAP) .......................................................................................................................... 25 

4-Methyl-alpha-pyrrolidinohexiophenone (MPHP) ............................................................................................................................... 25 

4-Methyl-alpha-pyrrolidinopropiophenone (4-MePPP) ........................................................................................................................ 25 

5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl-phenol .......................................................................................................... 50 

5-(1,1-Dimethyloctyl)-2-[(1R,3S)3-hydroxycyclohexyl-phenol (cannabicyclohexanol or CP-47,497 C8-homolog) ............................. 40 

5F-CUMYL-PINACA ............................................................................................................................................................................ 25 

5F-EDMB-PINACA ............................................................................................................................................................................... 25 

5F-MDMB-PICA ................................................................................................................................................................................... 25 

5F-AB-PINACA; N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide ............................................ 25 

5F-CUMYL-P7AICA; (1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboximide) ..................................... 25 

5F-ADB; 5F-MDMB-PINACA (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) ............................ 30 


khammond on DSKJM1Z7X2PROD with NOTICES4
77246 Federal Register / Vol. 85, No. 231 / Tuesday, December 1, 2020 / Notices 

Basic class 

Final revised 

2020 quotas 

(g) 

5F-AMB (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate) ................................................................... 30 

5F-APINACA; 5F-AKB48 (N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide) ........................................................ 30 

5-Fluoro-PB-22; 5F-PB-22 ................................................................................................................................................................... 20 

5-Fluoro-UR144, XLR11 ([1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone ........................................... 25 

5-Methoxy-3,4-methylenedioxyamphetamine ...................................................................................................................................... 25 

5-Methoxy-N,N-diisopropyltryptamine .................................................................................................................................................. 25 

5-Methoxy-N,N-dimethyltryptamine ..................................................................................................................................................... 25 

AB-CHMINACA .................................................................................................................................................................................... 30 

AB-FUBINACA ..................................................................................................................................................................................... 50 

AB-PINACA .......................................................................................................................................................................................... 30 

ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) .................................. 30 

Acetorphine .......................................................................................................................................................................................... 25 

Acetyl Fentanyl .................................................................................................................................................................................... 100 

Acetyl-alpha-methylfentanyl ................................................................................................................................................................. 30 

Acetyldihydrocodeine ........................................................................................................................................................................... 30 

Acetylmethadol .................................................................................................................................................................................... 25 

Acryl Fentanyl ...................................................................................................................................................................................... 25 

ADB-PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) ...................................................... 50 

AH-7921 ............................................................................................................................................................................................... 30 

Allylprodine .......................................................................................................................................................................................... 25 

Alphacetylmethadol .............................................................................................................................................................................. 25 

Alpha-Ethyltryptamine .......................................................................................................................................................................... 25 

Alphameprodine ................................................................................................................................................................................... 25 

Alphamethadol ..................................................................................................................................................................................... 25 

Alphaprodine ........................................................................................................................................................................................ 25 

Alpha-Methylfentanyl ........................................................................................................................................................................... 30 

Alpha-Methylthiofentanyl ...................................................................................................................................................................... 30 

Alpha-Methyltryptamine (AMT) ............................................................................................................................................................ 25 

Alpha-Pyrrolidinobutiophenone (a-PBP) ............................................................................................................................................. 25 

Alpha-Pyrrolidinoheptaphenone (PV8) ................................................................................................................................................ 25 

Alpha-Pyrrolidinohexanophenone (a-PHP) ......................................................................................................................................... 25 

Alpha-Pyrrolidinopentiophenone (a-PVP) ........................................................................................................................................... 25 

Aminorex .............................................................................................................................................................................................. 25 

Anileridine ............................................................................................................................................................................................ 20 

APINACA, AKB48 (N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide) ....................................................................................... 25 

Benzethidine ........................................................................................................................................................................................ 25 

Benzylmorphine ................................................................................................................................................................................... 30 

Betacetylmethadol ............................................................................................................................................................................... 25 

Beta-Hydroxy-3-methylfentanyl ............................................................................................................................................................ 30 

Beta-Hydroxyfentanyl ........................................................................................................................................................................... 30 

Beta-Hydroxythiofentanyl ..................................................................................................................................................................... 30 

Betameprodine ..................................................................................................................................................................................... 25 

Betamethadol ....................................................................................................................................................................................... 4 

Betaprodine .......................................................................................................................................................................................... 25 

Bufotenine ............................................................................................................................................................................................ 15 

Butylone ............................................................................................................................................................................................... 25 

Butyryl fentanyl .................................................................................................................................................................................... 30 

Cathinone ............................................................................................................................................................................................. 40 

Clonitazene .......................................................................................................................................................................................... 25 

Codeine methylbromide ....................................................................................................................................................................... 30 

Codeine-N-oxide .................................................................................................................................................................................. 192 

Cyclopentyl Fentanyl ........................................................................................................................................................................... 30 

Cyclopropyl Fentanyl ........................................................................................................................................................................... 20 

Cyprenorphine ..................................................................................................................................................................................... 25 

Desomorphine ...................................................................................................................................................................................... 25 

Dextromoramide .................................................................................................................................................................................. 25 

Diampromide ........................................................................................................................................................................................ 20 

Diethylthiambutene .............................................................................................................................................................................. 20 

Diethyltryptamine ................................................................................................................................................................................. 25 

Difenoxin .............................................................................................................................................................................................. 9,200 

Dihydromorphine .................................................................................................................................................................................. 753,500 

Dimenoxadol ........................................................................................................................................................................................ 25 

Dimepheptanol ..................................................................................................................................................................................... 25 

Dimethylthiambutene ........................................................................................................................................................................... 20 

Dimethyltryptamine .............................................................................................................................................................................. 50 

Dioxaphetyl butyrate ............................................................................................................................................................................ 25 

Dipipanone ........................................................................................................................................................................................... 25 

Drotebanol ........................................................................................................................................................................................... 25 

Ethylmethylthiambutene ....................................................................................................................................................................... 25 

Etonitazene .......................................................................................................................................................................................... 25 

Etorphine .............................................................................................................................................................................................. 30 


khammond on DSKJM1Z7X2PROD with NOTICES4
Federal Register / Vol. 85, No. 231 / Tuesday, December 1, 2020 / Notices 77247 

Basic class 

Final revised 

2020 quotas 

(g) 

Etoxeridine ........................................................................................................................................................................................... 25 

Fenethylline .......................................................................................................................................................................................... 30 

Fentanyl related substances ................................................................................................................................................................ 600 

FUB-144 ............................................................................................................................................................................................... 25 

FUB-AKB48 ......................................................................................................................................................................................... 25 

FUB-AMB, MMB-Fubinaca, AMB-Fubinaca ........................................................................................................................................ 25 

Furanyl fentanyl ................................................................................................................................................................................... 30 

Furethidine ........................................................................................................................................................................................... 25 

Gamma Hydroxybutyric Acid ............................................................................................................................................................... 29,417,000 

Heroin .................................................................................................................................................................................................. 45 

Hydromorphinol .................................................................................................................................................................................... 40 

Hydroxypethidine ................................................................................................................................................................................. 25 

Ibogaine ............................................................................................................................................................................................... 30 

Isobutyryl Fentanyl ............................................................................................................................................................................... 25 

JWH-018 and AM678 (1-Pentyl-3-(1-naphthoyl)indole) ...................................................................................................................... 35 

JWH-019 (1-Hexyl-3-(1-naphthoyl)indole) ........................................................................................................................................... 45 

JWH-073 (1-Butyl-3-(1-naphthoyl)indole) ............................................................................................................................................ 45 

JWH-081 (1-Pentyl-3-(1-(4-methoxynaphthoyl)indole) ........................................................................................................................ 30 

JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole) ........................................................................................................................... 30 

JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole) ............................................................................................................... 35 

JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole) ............................................................................................................................ 30 

JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole) ........................................................................................................................ 30 

JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole) ............................................................................................................................ 30 

Ketobemidone ...................................................................................................................................................................................... 30 

Levomoramide ..................................................................................................................................................................................... 25 

Levophenacylmorphan ......................................................................................................................................................................... 25 

Lysergic acid diethylamide (LSD) ........................................................................................................................................................ 40 

MAB-CHMINACA; ADB-CHMINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3- 

carboxamide) .................................................................................................................................................................................... 30 

MDMB-CHMICA; MMB-CHMINACA (methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate) ............... 30 

MDMB-FUBINACA (methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) ........................................... 30 

MMB-CHMICA (AMB-CHMICA); Methyl-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate ............................. 25 

Marihuana ............................................................................................................................................................................................ 3,200,000 

Mecloqualone ....................................................................................................................................................................................... 30 

Mescaline ............................................................................................................................................................................................. 25 

Methaqualone ...................................................................................................................................................................................... 60 

Methcathinone ..................................................................................................................................................................................... 25 

Methoxyacetyl fentanyl ........................................................................................................................................................................ 30 

Methyldesorphine ................................................................................................................................................................................. 5 

Methyldihydromorphine ........................................................................................................................................................................ 25 

Morpheridine ........................................................................................................................................................................................ 25 

Morphine methylbromide ..................................................................................................................................................................... 5 

Morphine methylsulfonate .................................................................................................................................................................... 5 

Morphine-N-oxide ................................................................................................................................................................................ 150 

MT-45 ................................................................................................................................................................................................... 30 

Myrophine ............................................................................................................................................................................................ 25 

NM2201; Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate ................................................................................................ 25 

N,N-Dimethylamphetamine .................................................................................................................................................................. 25 

Naphyrone ........................................................................................................................................................................................... 25 

N-Ethyl-1-phenylcyclohexylamine ........................................................................................................................................................ 25 

N-Ethyl-3-piperidyl benzilate ................................................................................................................................................................ 10 

N-Ethylamphetamine ........................................................................................................................................................................... 24 

N-Ethylhexedrone ................................................................................................................................................................................ 25 

N-Ethylpentylone, ephylone ................................................................................................................................................................. 30 

N-Hydroxy-3,4-methylenedioxyamphetamine ...................................................................................................................................... 24 

N-Methyl-3-Piperidyl Benzilate ............................................................................................................................................................ 30 

Nicocodeine ......................................................................................................................................................................................... 25 

Nicomorphine ....................................................................................................................................................................................... 25 

Noracymethadol ................................................................................................................................................................................... 25 

Norlevorphanol ..................................................................................................................................................................................... 55 

Normethadone ..................................................................................................................................................................................... 25 

Normorphine ........................................................................................................................................................................................ 40 

Norpipanone ........................................................................................................................................................................................ 25 

Ocfentanil ............................................................................................................................................................................................. 25 

Ortho-fluorofentanyl, 2-fluorofentanyl .................................................................................................................................................. 30 

Para-chloroisobutyryl fentanyl ............................................................................................................................................................. 30 

Para-fluorofentanyl ............................................................................................................................................................................... 25 

Para-fluorobutyryl fentanyl ................................................................................................................................................................... 25 

Para-methoxybutyryl fentanyl .............................................................................................................................................................. 30 

Parahexyl ............................................................................................................................................................................................. 5 

PB-22; QUPIC ..................................................................................................................................................................................... 20 


khammond on DSKJM1Z7X2PROD with NOTICES4
77248 Federal Register / Vol. 85, No. 231 / Tuesday, December 1, 2020 / Notices 

Basic class 

Final revised 

2020 quotas 

(g) 

Pentedrone .......................................................................................................................................................................................... 25 

Pentylone ............................................................................................................................................................................................. 25 

Phenadoxone ....................................................................................................................................................................................... 25 

Phenampromide ................................................................................................................................................................................... 25 

Phenomorphan .................................................................................................................................................................................... 25 

Phenoperidine ...................................................................................................................................................................................... 25 

Pholcodine ........................................................................................................................................................................................... 5 

Piritramide ............................................................................................................................................................................................ 25 

Proheptazine ........................................................................................................................................................................................ 25 

Properidine ........................................................................................................................................................................................... 25 

Propiram .............................................................................................................................................................................................. 25 

Psilocybin ............................................................................................................................................................................................. 30 

Psilocyn ................................................................................................................................................................................................ 50 

Racemoramide ..................................................................................................................................................................................... 25 

SR-18 and RCS-8 (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole) ........................................................................................... 45 

SR-19 and RCS-4 (1-Pentyl-3-[(4-methoxy)-benzoyl]indole) .............................................................................................................. 30 

Tetrahydrocannabinols ........................................................................................................................................................................ 384,460 

Tetrahydrofuranyl fentanyl ................................................................................................................................................................... 15 

Thebacon ............................................................................................................................................................................................. 25 

Thiafentanil .......................................................................................................................................................................................... 25 

Thiofentanyl ......................................................................................................................................................................................... 25 

THJ-2201 ([1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone) ...................................................................................... 30 

Tilidine .................................................................................................................................................................................................. 25 

Trimeperidine ....................................................................................................................................................................................... 25 

UR-144 (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone ...................................................................................... 25 

U-47700 ............................................................................................................................................................................................... 30 

Valeryl fentanyl .................................................................................................................................................................................... 25 

Schedule II 

1-Phenylcyclohexylamine .................................................................................................................................................................... 15 

1-Piperidinocyclohexanecarbonitrile .................................................................................................................................................... 25 

4-Anilino-N-phenethyl-4-piperidine (ANPP) ......................................................................................................................................... 934,956 

Alfentanil .............................................................................................................................................................................................. 3,260 

Alphaprodine ........................................................................................................................................................................................ 25 

Amobarbital .......................................................................................................................................................................................... 20,100 

Amphetamine (for conversion) ............................................................................................................................................................ 14,137,578 

Amphetamine (for sale) ....................................................................................................................................................................... 44,330,000 

Bezitramide .......................................................................................................................................................................................... 25 

Carfentanil ............................................................................................................................................................................................ 20 

Cocaine ................................................................................................................................................................................................ 73,090 

Codeine (for conversion) ..................................................................................................................................................................... 3,225,000 

Codeine (for sale) ................................................................................................................................................................................ 35,341,292 

Dextropropoxyphene ............................................................................................................................................................................ 35 

Dihydrocodeine .................................................................................................................................................................................... 156,713 

Dihydroetorphine .................................................................................................................................................................................. 25 

Diphenoxylate (for conversion) ............................................................................................................................................................ 14,100 

Diphenoxylate (for sale) ....................................................................................................................................................................... 770,800 

Ecgonine .............................................................................................................................................................................................. 78,439 

Ethylmorphine ...................................................................................................................................................................................... 30 

Etorphine hydrochloride ....................................................................................................................................................................... 32 

Fentanyl ............................................................................................................................................................................................... 934,956 

Glutethimide ......................................................................................................................................................................................... 25 

Hydrocodone (for conversion) ............................................................................................................................................................. 1,250 

Hydrocodone (for sale) ........................................................................................................................................................................ 33,997,285 

Hydromorphone ................................................................................................................................................................................... 3,512,651 

Isomethadone ...................................................................................................................................................................................... 30 

Levo-alphacetylmethadol (LAAM) ........................................................................................................................................................ 25 

Levomethorphan .................................................................................................................................................................................. 30 

Levorphanol ......................................................................................................................................................................................... 31,730 

Lisdexamfetamine ................................................................................................................................................................................ 21,000,000 

Meperidine ........................................................................................................................................................................................... 1,119,862 

Meperidine Intermediate-A .................................................................................................................................................................. 30 

Meperidine Intermediate-B .................................................................................................................................................................. 30 

Meperidine Intermediate-C .................................................................................................................................................................. 30 

Metazocine ........................................................................................................................................................................................... 15 

Methadone (for sale) ........................................................................................................................................................................... 25,619,700 

Methadone Intermediate ...................................................................................................................................................................... 27,673,600 

Methamphetamine ............................................................................................................................................................................... 1,224,109 


khammond on DSKJM1Z7X2PROD with NOTICES4
Federal Register / Vol. 85, No. 231 / Tuesday, December 1, 2020 / Notices 77249 

Basic class 

Final revised 

2020 quotas 

(g) 

[678,878 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 505,231 grams for methamphetamine mostly for 

conversion to a schedule III product; and 40,000 grams for methamphetamine (for sale).] 

Methylphenidate ................................................................................................................................................................................... 57,438,334 

Metopon ............................................................................................................................................................................................... 25 

Moramide-intermediate ........................................................................................................................................................................ 25 

Morphine (for conversion) .................................................................................................................................................................... 3,376,696 

Morphine (for sale) .............................................................................................................................................................................. 33,756,703 

Nabilone ............................................................................................................................................................................................... 62,000 

Norfentanyl ........................................................................................................................................................................................... 25 

Noroxymorphone (for conversion) ....................................................................................................................................................... 22,044,741 

Noroxymorphone (for sale) .................................................................................................................................................................. 376,000 

Opium (powder) ................................................................................................................................................................................... 250,000 

Opium (tincture) ................................................................................................................................................................................... 530,837 

Oripavine .............................................................................................................................................................................................. 33,010,750 

Oxycodone (for conversion) ................................................................................................................................................................ 725,998 

Oxycodone (for sale) ........................................................................................................................................................................... 65,667,554 

Oxymorphone (for conversion) ............................................................................................................................................................ 28,204,371 

Oxymorphone (for sale) ....................................................................................................................................................................... 658,515 

Pentobarbital ........................................................................................................................................................................................ 25,850,000 

Phenazocine ........................................................................................................................................................................................ 25 

Phencyclidine ....................................................................................................................................................................................... 35 

Phenmetrazine ..................................................................................................................................................................................... 25 

Phenylacetone ..................................................................................................................................................................................... 40 

Piminodine ........................................................................................................................................................................................... 25 

Racemethorphan ................................................................................................................................................................................. 5 

Racemorphan ...................................................................................................................................................................................... 5 

Remifentanil ......................................................................................................................................................................................... 3,000 

Secobarbital ......................................................................................................................................................................................... 172,100 

Sufentanil ............................................................................................................................................................................................. 4,000 

Tapentadol ........................................................................................................................................................................................... 13,447,541 

Thebaine .............................................................................................................................................................................................. 59,284,070 

List I Chemicals 

Ephedrine (for conversion) .................................................................................................................................................................. 100 

Ephedrine (for sale) ............................................................................................................................................................................. 4,756,000 

Phenylpropanolamine (for conversion) ................................................................................................................................................ 14,100,000 

Phenylpropanolamine (for sale) ........................................................................................................................................................... 16,590,000 

Pseudoephedrine (for conversion) ...................................................................................................................................................... 1,000 

Pseudoephedrine (for sale) ................................................................................................................................................................. 200,382,900 

The Acting Administrator further 

proposes that APQ for all other schedule 

I and II controlled substances included 

in 21 CFR 1308.11 and 1308.12 remain 

at zero. 

Timothy J. Shea, 

Acting Administrator. 

[FR Doc. 2020–26443 Filed 11–30–20; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

DEPARTMENT OF THE INTERIOR 

DEPARTMENT OF COMMERCE 

National Oceanic and Atmospheric 

Administration 

Notice of Lodging of Proposed 

Consent Decree Under the 

Comprehensive Environmental 

Response, Compensation, and Liability 

Act (CERCLA), the Clean Water Act 

(CWA), and the Oil Pollution Act (OPA) 

and Notice of Availability of Draft 

Restoration Plan/Environmental 

Assessment of Restoration Project 

Incorporated Into Proposed Consent 

Decree 

On November 12, 2020, the 

Department of Justice lodged a proposed 

consent decree with the United States 

District Court for the Western District 

Washington in the lawsuit entitled 

United States of America, State of 

Washington, Suquamish Tribe, and 

Muckleshoot Indian Tribe v. City of 

Seattle, Civil Action No. 16–1486 (W.D. 

Wa.). 

The complaint asserts claims for 

natural resource damages by the United 

States on behalf of the National Oceanic 

and Atmospheric Administration and 

the Department of the Interior; the State 

of Washington; the Suquamish Tribe; 

and the Muckleshoot Indian Tribe 

(collectively, the ‘‘Natural Resource 

Trustees’’) pursuant to the section 

107(a) of the Comprehensive 

Environmental Response, 

Compensation, and Liability Act 

(CERCLA), 42 U.S.C. 9607(a); section 

311 of the Clean Water Act (CWA), 33 

U.S.C. 1321; section 1002(b) of the Oil 

Pollution Act (OPA), 33 U.S.C. 2702(b); 

and the Washington Model Toxics 

Control Act (MTCA), RCW 70.105D. 


khammond on DSKJM1Z7X2PROD with NOTICES4